NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- anti-CD20/CD3 monoclonal antibody XmAb13676
A bispecific, Fc domain-containing, monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 monoclonal antibody XmAb13676 contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, XmAb13676 binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell-mediated tumor cell killing because the agent is able to bind to Fc receptors. Check for active clinical trials using this agent. (NCI Thesaurus)
Synonym: anti-CD20 x anti-CD3 bispecific monoclonal antibody XmAb13676 Code name: XmAb13676